The endogenous cardiac steroid-like compounds, endogenous ouabain (EO) in particular, are present in the human circulation and are considered putative ligands of the inhibitory binding site of the plasma membrane Na ϩ -K ϩ -ATPase. A vast amount of data shows that, when added to cell cultures, these steroids promote the growth of cardiac, vascular, and epithelial cells. However, the involvement of the endogenous compounds in the regulation of cell viability and proliferation has never been addressed experimentally. In this study, we show that EO is present in mammalian sera and cerebral spinal fluid, as well as in commercial bovine and horse sera. The lowering of serum EO concentration by the addition of specific anti-ouabain antibodies caused a decrease in the viability of several cultured cell lines. Among these, neuronal NT2 cells were mostly affected, whereas no reduction in viability was seen in rat neuroendocrine PC12 and monkey kidney COS-7 cells. The anti-ouabain antibody-induced reduction in NT2 cell viability was significantly attenuated by the addition of ouabain and was not observed in cells growing in serum-free media. Furthermore, the addition to the medium of low concentrations (nM) of the cardenolide ouabain, but not of the bufadienolide bufalin, increased NT2 and PC12 cell viability and proliferation. In addition, at these concentrations both ouabain and bufalin caused the activation of ERK1/2 in the NT2 cells. The specific ERK1/2 inhibitor U0126 inhibited both the ouabain-induced activation of the enzyme and the increase in cell viability. Furthermore, anti-ouabain antibodies attenuated serum-stimulated ERK1/2 activity in NT2 but not in PC12 cells. Cumulatively, our results suggest that EO plays a significant role in the regulation of cell viability. In addition, our findings support the notion that activation of the ERK1/2 signaling pathway is obligatory but not sufficient for the induction of cell viability by EO.
CARDIAC STEROID (CS) IS A general term for cardenolides such as ouabain and digoxin and for bufadienolides such as bufalin and marinobufagenin prepared from plants and toad skin. Administration of these compounds to animals and humans causes an increase in the force of contraction of heart muscle and stabilizes heart rate (for review, see Refs. 36, 59) . Therefore, these compounds have been used for centuries in Western and Eastern medicine to treat heart failure, atrial fibrillation, and other maladies. The pharmacological profile of the positive inotropic effect of CS was attributed to their ability to bind to and inhibit the Na ϩ -K ϩ -ATPase (see below). However, numerous recent studies (33, 34) revealed that some of the CS-induced effects do not correlate with the ability of CS to inhibit Na ϩ and K ϩ pumping per se. Although all CS have a similar chemical structure, a steroid core, a five-membered or six-membered lactone ring, and, in most cases, a sugar moiety, their effects at the molecular, cellular, and systemic levels are highly diverse (16) .
Based on theoretical and physiological considerations, it was postulated that endogenous cardiac steroid-like compounds (ECS) are also present in mammalian tissues (13, 60) . Endogenous ouabain (EO) was identified in human plasma and in the adrenal gland (18, 58) , 19-norbufalin and its peptide derivative were identified in cataractous human lenses (35) , and a marinobufogenin-like compound and telocinobufagin were identified in human urine and plasma, respectively (5, 28) . Although the entire biosynthetic pathway for ECS has not been elucidated, extensive data support the notion that they are synthesized in the adrenal gland: ECS are present at relatively high concentrations in the adrenal gland and adrenalectomy leads to a drop in EO plasma levels (43) . Several investigators (19, 37, 53) , using a radioactive tracer chase, showed that the adrenal cortex can synthesize ECS and that the biosynthetic pathway is similar to that of other steroids. Furthermore, Takahashi and colleagues (29, 65) have demonstrated the synthesis of EO in adrenocortical PC12 cells, which are often used as a model system for sympathetic neuronal cell function and differentiation, and in immortalized hypothalamic N1 cells. Na ϩ -K ϩ -ATPase, an enzyme present in the plasma membrane of most eukaryotic cells, is the established receptor for CS and ECS. The enzyme, a heterodimer consisting of catalytic ␣-and regulatory ␤-and FXYD-subunits, plays a key role in the maintenance of electrochemical gradients of monovalent cations across the plasma membrane (7, 22) . CS bind to a specific site on the ␣-subunit of the Na ϩ -K ϩ -ATPase and inhibit its activity (39, 52) . In addition to inhibiting ion transport, the binding leads to the caveolin-mediated interaction of Na ϩ -K ϩ -ATPase with the membrane-associated nonreceptor tyrosine kinase Src and activation of diverse signaling pathways. These were suggested to include extracellular responsive kinase (ERK), phosphatidylinositol 3-kinase (PI3K), PI3K-dependent protein kinase B, phospholipase C, intracellular Ca 2ϩ concentration oscillations, and increased production of reactive oxygen species (46, 57) . Some of these pathways have been established to be tightly involved in the regulation of cell growth.
Critical cellular decisions such as viability, proliferation, and differentiation, are regulated by stimulatory cues from the extracellular environment, primarily growth factors, extracellular matrix proteins, and adhesion molecules located on the surface of neighboring cells. These extracellular cues are converted into a cellular response through their binding to specific receptors present at the surface of the recipient cell. Many growth factors bind and activate transmembrane glycoproteins of the receptor tyrosine kinase family (8, 64) . One of the best characterized signaling pathways of this family is the mitogen-activated protein kinase cascade, also called ERK.
The direct activation and transactivation of this signaling pathway results in modulation of target proteins, as well as in activation of transcription factors, leading to cellular alterations in viability and proliferation (23) .
Numerous studies have shown that CS have a dual stimulatory/inhibitory effect on cell viability and proliferation: the addition of exogenous ouabain at relatively low concentrations has been shown to induce proliferation in smooth muscle, astrocytes, and endothelial and renal epithelial cells (1, 48, 50) . Bufalin was shown to stimulate the differentiation of several cancer cells (49, 66) . At higher concentrations, ouabain (31) and bufalin (42) induced apoptosis in various cell types. The mechanism by which CS affect cell growth is not fully understood, but recent studies (62, 63) indicate that it is independent of intracellular Na ϩ and K ϩ concentration and involves the signaling pathways stimulated by the steroids and recycling of the Na ϩ -K ϩ -ATPase in the cell. The notion that EO participates in the regulation of cell viability has, to the best of our knowledge, not been addressed experimentally and is the aim of this study. We show that EO is present in mammalian serum and cerebrospinal fluid (CSF) and in commercial bovine and horse sera. We provide evidence that a reduction in serum EO concentration, using anti-ouabain antibodies, causes the attenuation of cell viability by a mechanism involving ERK1/2 activation.
MATERIALS AND METHODS
Materials. DMEM, RPMI-1640, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), protease inhibitor cocktail, N,N,-dimethyl formamide, SDS, Ponceau S, horseradish peroxidaseconjugated secondary goat anti-rabbit IgG antibody, and UO126 ethanolate were obtained from Sigma (St. Louis, MO, USA). [ 3 H]thymidine was purchased from New England Nuclear (Boston, MA), donor horse serum, FBS, L-glutamine, pen-strep, trypsin-EDTA, and ECL-KIT were purchased from Biological Industries. Pathscan Multiplex Western Cocktail I containing antibodies against phosphop90RSK, phospho-Akt, phospho-p42/44 mitogen-activated protein kinase (ERK1/2), phospho-S6, and eIF4E was obtained from Cell Signaling (Danvers, MA). Type-I rat tail collagen was obtained from BD Biosciences (Bedford, MA). Bio-Rad protein reagent and Precision plus protein standards were obtained from Bio-Rad (Hercules, CA), and emulsifying scintillation fluid was obtained from Zinsser Analytic (Frankfurt, Germany). Protein A-Sepharose CL-4B beads were purchased from Pharmacia Biotech (Uppsala, Sweden), and Sep-Pak C 18 columns were from Waters (Milford, MA).
Human CSF and animal sera. Human CSF samples were obtained from the Human Brain and Spinal Fluid Resource Center (Los Angeles, CA). Human serum was obtained from healthy blood donors at the Blood Bank, Hadassah Hospital (Jerusalem, Israel). Animal sera were obtained from a local slaughter house (cow) and from animals that were used for other experiments (rabbit, rat, and mouse) and housed at the Hebrew University Animal House. The joint ethics committee (Institutional Animal Care and Use Committee) of the Hebrew University and Hadassah Medical Center approved the study protocol for animal welfare. The Hebrew University is an Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited institute.
Cell culture. NT2 (human neuronal precursor cells), HEK293 (human embryonic kidney cells), COS7 (monkey kidney cells), and OK (opossum kidney cells) were cultured in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin in 5% CO 2 at 37°C. PC12 cells were grown in the same medium supplemented with 7% FBS and 7% horse serum. H441 and H460 (human lung) and COLO-205 (human colon) cancer cells were grown in RPMI-1640 medium supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin in 5% CO 2 at 37°C. For the experiments, the cells were cultured in 96-well flat-bottom tissue culture plates coated with 200 g/ml type-I rat tail collagen. After 24-h preincubation in complete medium, the medium was replaced with serum-free, 1% FBS, or complete medium containing different concentrations of ouabain or bufalin for 24 h. In experiments in which the effect of anti-ouabain antibodies was tested, the cells were grown in complete medium for 24 h and then exposed to complete or serum-free medium previously incubated with antiouabain antibodies or rabbit IgG for 24 h.
Determinations of cell viability and proliferation. Cell viability was determined using the conventional MTT assay. MTT was dissolved in PBS at a concentration of 5 mg/ml. Twenty five microliters of this solution were added to each well, and the plates were incubated at 37°C for 2 h. The assay was terminated by the addition of 100 l/well of an aqueous solution of 20% wt/vol SDS, 50% vol/vol N,N,-dimethyl formamide and cell incubation at 37°C for 1 h. Absorbance was measured with an ELISA-plate reader (Bio-Tek Instruments) at 570 nm to quantify the amount of formazan product, which reflects the number of viable cells in culture (20) . In view of the demonstration that MTT staining in ouabain-treated cells is not sufficient methodology for quantification of Madin-Darby canine kidney cell viability (3), we performed preliminary experiments matching cell viability determined by MTT, cell count, and protein determinations. The results of these experiments validated the use of MTT assay in our experimental systems (data not shown).
Protein content was determined by the Bradford assay according to the manufacturer's instructions (10) Western blot. Cells were rinsed with PBS and lysed with 150 l RIPA buffer (150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 50 mM Tris·HCl pH 8, 1 mM NaVO4, and protease inhibitor cocktail at a 1:100 dilution). Cell lysates were scraped and centrifuged for 10 min at 14,000 g at 4°C, and aliquots of the supernatants were stored at Ϫ70°C until use. Protein samples were diluted in loading buffer [SDS containing 375 mM Tris pH 6.8, 10% (wt/vol) SDS, 60% (vol/vol) glycerol, 1% 2-␤-mercaptoethanol (vol/ vol), 0.1% (wt/vol), and bromophenol blue and incubated at 95°C for 5 min]. SDS-PAGE was used to separate proteins on a 12% gel. Proteins were loaded onto the gel (20 g/40 l) and subjected to electrophoresis for 1.5-2 h at 100V with protein standards and transferred to a polyvinylidene fluoride membrane (PVDF Immubilon P; 0.45 m, Millipore). The presence of transferred proteins on the blot and their equal quantity in all lines were confirmed by staining with Ponceau S reagent. After being blocked with TBS containing 0.1% (vol/vol) Tween and 5% (wt/vol) skim milk for 1 h at room temperature, the membranes were incubated overnight at 4°C with a cocktail of specific antibodies including anti-phosphor-ERK1/2 and anti-eIF4E (used as an internal standard for equal protein loading). Next, the membranes were washed with TBS containing 0.1% Tween and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary goat anti-rabbit IgG antibody (1: 50,000). Additional washes in TBS were followed by antibody detection, using an ECL-KIT, according to the manufacturer's instructions. Signals were visualized on Kodak BioMax film and quantified by densitometry (Fluro-s Multilmager; Bio-Rad).
Extraction and determination of EO. The EO levels in animal sera, commercially available tissue culture sera, and human CSF were determined using a specific and sensitive ELISA based on antiouabain antibodies. EO was extracted and determined as previously described (38) . In brief, EO was extracted by the addition of 0.1% trifluoroacetic acid solution. Following centrifugation (15 min, 28,500 g), the clear supernatant was loaded onto a Sep-Pak C 18 column, which was then washed with 10 ml H2O containing 0.1% trifluoroacetic acid, and the bound EO was eluted with 80% acetonitrile. The solvent was evaporated, and the residue was dissolved in PBS. The determination of EO was based on a specific and sensitive competitive inhibition ELISA involving anti-ouabain antibodies (see below).
Preparation and concentration of anti-ouabain antibody. Antiouabain antibodies were prepared as previously described (38) . In brief, ouabain-BSA conjugate, subsequently used to immunize rabbits, was prepared as described by Masugi at al (44) . A total of 500 mg ouabain-BSA in complete Freund's adjuvant was injected intramuscularly and subcutaneously into 3 to 4-mo-old-rabbits. The animals were rechallenged as above seven times at 6-wk intervals, with the same amount of antigen emulsified in incomplete Freund's adjuvant. The collected rabbit sera were used at 1:4,000 in the EO ELISA or without dilution to determine antibody concentration (see below).
The antibodies are highly specific for ouabain and cross-react only with ouabagenin (53%), strophantidine (16.5%), digoxin (0.76%), and bufalin (0.6%). Other steroids, including cholesterol, testosterone, progesterone, corticosterone, 17-hydroxy pregnenolone, and 21-deoxycortisol, do not cross-react with the antibodies, even at 10 M (37).
For the concentration of anti-ouabain antibodies, protein A-Sepharose CL-4B beads and columns were prepared according to the manufacturer's instructions. Volumes of 2.5 ml rabbit plasma containing anti-ouabain antibodies were loaded onto the columns. Unbound immunoglobulins were eluted with PBS. Bound immunoglobulins were then eluted with glycine buffer (0.2 M glycine and 0.2 M NaCl pH 3) into tubes containing 50 l of 1 M Na 2HPO4. The presence and quantification of anti-ouabain antibodies in the eluant was determined using ELISA as described above. The purified antibody was concentrated by centrifugation (5,000 g), using Centricon (Millipore/Amicon, Carrigtwohill, Ireland) centrifugal filter units (3,000-NMWL membrane). The concentrated anti-ouabain antibodies were dialyzed overnight against saline in a cellulose tubular dialysis membrane (6,000 -50,000 cutoff, nominal pore size of ϳ0.002 m; Spectrapor Medical), which was first incubated in boiling water containing 1 mM EDTA, 2% Na 2CO3 for 20 min. The dialyzed antibodies were used in the cell viability measurements.
Determination of EO by ELISA. A sensitive, competitive inhibition ELISA was designed for the quantification of EO. In this assay, samples were tested for their ability to inhibit the specific binding of the rabbit antibodies to solid phase-bound ouabain. The entire procedure was as previously described with no modifications (37) .
Determination of serum estradiol, testosterone, free T4, and insulin. The levels of estradiol, testosterone, free T4, and insulin in serum were determined at the Clinical Biochemistry Department of the Hadassah Hospital, using the IMMULITE 2500 immunoassay system (Siemens Healthcare Diagnostics), based on solid-phase, chemiluminescent competitive analog immunoassays.
Statistical analyses. The data are expressed as means Ϯ SE. Student's t-test, paired t-test, one-way ANOVA with post hoc t-tests, and Mann-Whitney test were applied when appropriate. P Ͻ 0.05 was considered statistically significant.
RESULTS
EO is present in CSF, animal sera, and commercial tissue culture sera. Numerous studies have identified EO as a normal constituent of animal sera and CSF (for review see Ref. 46 ). The concentration of EO in these body fluids was found to be extremely variable, presumably due to the different physiological states of the animals in the various studies and the detection method used for its quantification (6, 46) . In agreement with previous reports, we detected EO in human and animal sera and human CSF at nanomolar concentrations (Fig. 1) . The EO levels were found to be more than double in rodents compared with the level in human or cow serum (Fig.  1) . Thus apparently all cells are in vivo exposed to EO circulating in the CSF or plasma. Furthermore, the presence of EO in cow serum suggested that commercial FBS and horse sera, essential supplements for growth of many cells in culture, also contain this steroid. Indeed, as shown in Fig. 1 , EO was detected in the two commercial sera at 3-4 nM, concentrations similar to those detected in the rodent serum. Hence, tissuecultured cells growing in the presence of 10% serum are continuously exposed to 0.3-to 0.4-nM concentrations of EO.
Anti-ouabain antibodies specifically reduce EO levels in FBS. A major approach in this study was to test the consequences of the reduction in EO levels in cell culture media on cell viability. This was achieved by the treatment of cell culture media with anti-ouabain antibodies. As mentioned above, the anti-ouabain antibodies used in this study are highly specific and in the ELISA do not interact with other tested steroids. The specificity was also challenged by incubating FBS with these antibodies. The incubation of medium containing FBS with 100 g/ml anti-ouabain antibodies decreased EO level by 87% (data not show). Incubation of medium containing FBS with 50 g/ml anti-ouabain antibodies decreased the EO level by ϳ70% (Fig. 2) . Importantly, this treatment did not change the levels of other steroids present in the serum, such as testosterone and estradiol, or the levels of other tested hormones such as free thyroxin 4 and insulin. These results confirm the specificity of the antibodies and their suitability for this study. Reduction of EO in tissue culture medium inhibits cell viability. The documented effect of exogenous ouabain on cell growth (see Introduction) and the presence of EO in cell culture media raised the possibility that the endogenous steroid participates in the regulation of cell viability. This possibility was addressed by investigating the effect of a reduction in serum EO, achieved by the incubation of complete cell medium with specific anti-ouabain antibodies, on cell viability. Cells grown in media previously incubated with normal rabbit IgG served as control. Screening of the effect of this treatment on several tissue culture cells available in our laboratory is shown in Fig. 3 . The viability of human colon cancer (COLO-205), lung adenocarcinoma epithelial (H441 and H460), human embryonic kidney (HEK), human neuronal teratocarcinoma (NT2), and opossum kidney (OK) cells was significantly inhibited when cells were grown in media previously incubated with anti-ouabain antibodies (100 g/ml). The cells most affected were the NT2 cell line, with Ͼ 30% reduction in viability, whereas the monkey kidney cell line (COS-7) and the rat neuroendocrine (PC12) cells were not affected. Hence, NT2 cell line was chosen for the proceeding experiments and PC12 cells, which were unaffected, were chosen for purposes of comparison because of their similar neuronal aspects. The detailed dose dependence of anti-ouabain antibodies on NT2 cell viability is shown in Fig. 4A . A significant reduction in NT2 cell viability was already seen when the cells were grown in medium preincubated for 24 h with 3.1 g/ml. Assuming that the molecular weight of the antibody is 150,000 Da, this concentration corresponds to 20 nM in the growth medium. The magnitude of the reduction in viability was dependent on anti-ouabain antibody concentration. At high concentrations, the growth level was reduced to that seen in cells growing in serum-free media (Fig. 4A) . The viability of the PC12 cells was not affected by any concentration of the anti-ouabain antibodies tested (Fig. 4A ). This may be consistent with the observation that these cells may release EO into the growth medium (see DISCUSSION) .
As shown above, the anti-ouabain antibodies used in this study are highly specific, and reduced serum EO but did not affect other serum steroids and other hormones. However, the possibility that these antibodies inhibited NT2 cell viability by a mechanism unrelated to the reduction in serum EO could not be ruled out. To address this issue, the growth of NT2 cells was also tested in serum-free DMEM (a well-defined solution without any detectable CS), which was preincubated with anti-ouabain antibodies. As depicted in Fig. 4B , the viability of NT2 cells was not affected by any anti-ouabain antibody concentration when serum-free medium was used. In addition, the effect of complete medium previously treated with antiouabain antibodies on NT2 cell growth was tested in the Fig. 2 . Effect of anti-ouabain antibodies treatment on different constituents in FBS. DMEM containing 10% FBS was incubated with 50 g/ml of anti-ouabain antibodies or normal rabbit IgG. After a 24-h incubation at 4°C, samples of the solutions were analyzed for the levels of different compounds, as described in MATERIALS AND METHODS. Results are expressed as %levels of the IgG-treated samples (means Ϯ SE of 6 experiments). *P Ͻ 0.001, significantly lower than control. Fig. 3 . Effect of anti-ouabain antibodies on the viability of different cell lines. Various cells were transferred to 96-well-plates and grown for 24 h in their corresponding complete media, as described in MATERIALS AND METHODS. Media were then replaced with the corresponding complete media previously incubated for 24 h at 4°C in the presence or absence of anti-ouabain antibodies (100 g/ml) or IgG (100 g/ml). Cell viability was assayed after 24 h using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) viability test. Values are expressed as the means Ϯ SE (error bars) of 23 determinations. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, significantly lower than nontreated medium. presence of exogenously added ouabain. As shown in Fig. 4C , in seven out of the eight experiments, the inhibition of NT2 cell growth by anti-ouabain antibody-treated medium was partially reversed by the addition of 10 nM ouabain (a concentration that did not affect NT2 cell growth, see below). The average growth inhibition in the presence of added ouabain was 68% of that seen in its absence. These results strongly support the notion that the observed anti-ouabain antibody effect is due to the reduction in EO.
Ouabain but not bufalin increases NT2 and PC12 cell viability and proliferation. The effect of exogenously added ouabain on cell viability has been extensively studied in epithelial, endothelial, and smooth muscle cells (see Introduction). The bimodal effect of the steroid, increased viability at low concentrations and inhibition of growth at high concentrations, was noticed in most previous studies. These observations, together with our finding of the effect resulted from reduction in EO on NT2 but not PC12 cell viability, prompted the investigation of the effect of exogenously added ouabain on the growth of these cells. Since in several experimental systems bufalin was shown to be more active than ouabain (51, 55) and as it manifests different effects on cell growth (see above), the effect of this steroid was also tested. The addition of ouabain to complete culture medium containing 1 or 10% serum (Fig. 5,  A and B, respectively) did not have any effect on NT2 cell viability. In contrast, when cells were grown in serum-free medium, the addition of 1 nM ouabain caused a small (1-20%) but significant increase in cell viability, estimated by MTT and protein determination assays (Fig. 5, C and D) . Increased viability in the MTT assay was observed in 11 out of the 12 experiments performed, 7 experiments showing a Ͼ10% increase. Under these conditions, ouabain at 0.1 nM also induced NT2 cell proliferation, estimated by [ 3 H]thymidine incorporation (Fig. 5E ). At higher concentrations (Ͼ100 nM), ouabain induced dose-dependent NT2 cell death (data not shown). Bufalin did not have stimulatory effect on the viability or proliferation of NT2 cells growing in the presence or absence of serum. However, the steroid had a more pronounced effect on NT2 cell death, compared with ouabain, which was apparent already at 1-10 nM (Fig. 5, A-E) .
The effects of ouabain and bufalin on PC12 cells are depicted in Fig. 6 . As the anti-ouabain antibodies did not affect µ µ Fig. 4 . Characterization of the effect of anti-ouabain antibodies on NT2 and PC12 cell viability. A: dose dependence of the effect of anti-ouabain antibodies on NT2 and PC12 cell viability. NT2 and PC12 cells were cultured in complete medium for 24 h as described in MATERIALS AND METHODS. Complete media containing different concentrations of anti-ouabain antibodies or IgG were preincubated for 24 h and added to the cell cultures. Cell viability was assayed after 24 h using the MTT viability test. B: lack of effect of anti-ouabain antibodies in serum-free medium. NT2 cells were cultured in complete medium for 24 h. Serum-free media containing different concentrations of antiouabain antibodies or IgG were preincubated for 24 h and added to the cell cultures and viability was assessed after an additional 24 h. C: partial reversal of anti-ouabain antibody-induced reduction in NT2 cell viability by ouabain. NT2 cells were cultured in complete medium for 24 h. Complete medium containing 25 g/ml of anti-ouabain antibodies in the presence or absence of 10 nM ouabain were preincubated for 24 h and added to cell cultures. Cell viability was assessed after 24 h. Each line represents separate experiment (*P Ͻ 0.05, **P Ͻ
in paired t-test).
PC12 cell viability, we predicted that the addition of exogenous ouabain would be ineffective. Surprisingly, however, ouabain had similar effects on the growth of PC12 cells as it had in NT2 cells: stimulating viability and proliferation in the range of 0.1-10 nM (Fig. 6 , C-E) but ineffective when added to medium supplemented with 1% or 10% serum (Fig. 6, A and  B) . At higher ouabain concentrations as in NT2 cells, it induced cell death (data not shown). Neither did bufalin display any Fig. 5 . Effect of ouabain and bufalin on NT2 cell viability and proliferation. NT2 cells were cultured in complete medium for 24 h. Different concentrations of ouabain (line) and bufalin (dashed line) were added for 24 h in complete medium (A), medium containing 1% serum (B) and serum-free medium (C-E). Following a 24-h incubation, cell viability was determined using the MTT assay (A-C), protein content using the Bradford assay (D), and cell proliferation by [ 3 H]thymidine incorporation (E). Values are expressed as the means Ϯ SE (error bars; n ϭ 6 -14; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001). Fig. 6 . Effect of ouabain and bufalin on PC12 cell viability and proliferation. PC12 cells were cultured in complete medium for 24 h. Experiments were performed as described in Fig. 5 . Values are expressed as the means Ϯ SE (error bars; n ϭ 6 -14; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001). stimulatory effect on viability or proliferation in PC12 cells (Fig. 6, A-E) . However, unlike its effect on NT2 cells, this steroid did not cause the death of PC12 cells even at relatively high (100 M) concentrations (data not shown).
Activation of ERK1/2 is involved in the ouabain-induced increase in NT2 cell viability.
It is well established that the interaction of ouabain with the Na ϩ -K ϩ -ATPase triggers an intracellular signaling reaction in various cell types: In many cells including myocytes (27) , epithelial (14) , vascular (4), polycystic kidney (48) , and OK (25) , it was demonstrated that the ouabain-induced cell growth is mediated by the activation of the ERK cascade. Hence, to address the mechanism involved in ouabain-induced cell growth in NT2 cells, we tested whether the ERK pathway is also involved in this phenomenon. As depicted in Fig. 7A , the addition of ouabain to NT2 cells growing in serum-free medium caused stimulation of ERK1/2. The stimulatory response showed a bell-shape dependence, with a maximal stimulation of 80% at 1 nM. Noteworthy, this concentration of ouabain was identical to that stimulating the viability of these cells (Fig. 5, C-D) , suggesting a causal relationship between the two. Pharmacological manipulation strengthened this notion The addition of the MEK inhibitor U0126, a highly selective blocker of the ERK1/2 pathway, totally prevented ouabain-induced ERK1/2 activation, in these cells, the values obtained being indistinguishable from those in the presence of the inhibitor alone (Fig. 8A) . The effect of U0126 was also tested on cell viability. As shown in Fig. 8B , the inhibitor, which by itself did not significantly affect NT2 cell viability, completely abolished the ouabaininduced stimulatory effect (Fig. 8B) . This finding supports the notion that ERK1/2 activation is part of the mechanisms governing the ouabain-induced stimulation of NT2 cell viability.
As bufalin did not induce stimulation of NT2 cell viability, we predicted that it would not have an effect on ERK1/2 activity in these cells. Surprisingly, however, as seen in Fig.  7B , bufalin had a similar effect to that of ouabain on ERK1/2 activation. These results indicate that although the activation of the ERK1/2 pathway is obligatory, it is not sufficient to induce the stimulation of NT2 cell viability by ouabain.
Reduction of EO in tissue culture medium inhibits ERK1/2 activity. It is well established that numerous serum components, including growth factors and hormones, stimulate cell viability and growth via the activation of the ERK1/2 signaling pathway (23). We show above that a reduction in EO by anti-ouabain antibodies leads to a decrease in NT2 but not PC12 cell viability. The involvement of ERK1/2 activation in the effect of exogenously added ouabain on NT2 cell viability Fig. 8 . Effect of the MEK inhibitor U0126 on ouabain-induced ERK activation and cell viability in NT2 cells. Ouabain effect in the presence or absence of U0126 (1 M) on ERK phosphorylation (A) and cell viability (B) were determined as described in Figs. 7 and 5 , respectively. Values are expressed as the means Ϯ SE (error bars; n ϭ 6 -9; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001). suggested that this pathway may also be involved in the effect of EO. This prompted us to test the effect of a reduction in EO in complete medium on serum-induced ERK1/2 activity. As seen in Fig. 9 , treatment of serum-supplemented medium previously preincubated with anti-ouabain antibodies reduced dramatically ERK1/2 phosphorylation in NT2, but not PC12 cells, to levels seen in cells grown in serum-free medium. These results suggest that EO has a constitutive effect on ERK1/2 phosphorylation in NT2 cells, which may be involved in the regulation of the viability of these cells.
DISCUSSION
Cellular growth, differentiation, and proliferation are controlled by numerous proteins and steroids, collectively termed growth factors, present in the plasma and extracellular fluid. The results of the present study show that EO, a serum, constituent, acts as a growth factor, affecting cell viability through activation of the ERK1/2 signaling pathway. This conclusion is based on the following observations: 1) a specific reduction in serum EO by the addition of anti-ouabain antibodies decreased the viability of several mammalian cells; 2) the reduction in NT2 cell viability by the anti-ouabain antibodies was dose dependent and was accompanied by a reduction in serum-induced ERK1/2 activation of these cells; and 3) the addition of ouabain to the medium of cells growing in the absence of serum stimulated NT2 cell viability and ERK1/2 phosphorylation, two phenomena that were inhibited by a specific inhibitor of the ERK1/2 pathway, U0126.
CS such as ouabain, 19-norbufalin, and marinobufagenin, were identified as normal constituents of human tissues and body fluids almost 20 yr ago. In agreement with previous publications, we show that human serum as well as serum from other animals and human CSF, contains EO at concentrations ranging from 0.1 to 5 nM. The values in human serum are directly comparable to other studies on normal individuals (41) as well as in numerous clinical studies (for review, see Ref. 40) . The levels of EO in FBS are significantly higher than those in cow serum (Fig. 1) . As fetal serum contains relatively high levels of growth factors compared with serum from adult animals, this high level is in agreement with the notion that EO serves as a growth factor. Furthermore, the relatively high EO level in FBS is in accord with findings from humans, showing that EO and other ECS are higher in neonates and umbilical arterial sera than in adult plasma (17, 21) . Evidently, serum EO levels in rodents are significantly higher than those found in other tested animals (Fig. 1) . This high concentration may represent the increased synthetic capabilities of ECS in rodents or may be accounted for by the demonstrated presence of CS in normal rodent chow (24) . Alternatively, since the rodent serum samples were most plausibly obtained under stressful or anoxic conditions this may have caused an increase in sera EO.
In addition, we show here for the first time that commercially available bovine and horse sera, which are routinely used as supplements for tissue culture media, also contain about 3.5 nM EO. Hence, all tissues and cells in vivo, and tissue-cultured cells, growing in media supplemented with bovine or horse serum are constantly exposed to nM concentrations of EO. This finding must be taken into consideration when studying molecular or cellular mechanisms related to the CS/Na
The addition of exogenous CS to cells and animals results in numerous biochemical and physiological responses (46) . These findings, together with the demonstration of the presence of ECS in mammals, were the basis for terming ECS "hormones" in several recent articles (2, 32, 56) . Other investigators question the possibility that ECS are synthesized in mammals and claim that these steroids are of dietary origin (26, 61) . This claim, however, is questionable in view of the very low absorbance of ouabain by the gastrointestinal tract (54) . Whether endogenously synthesized or not, the biological consequences of the EO present in the serum, as demonstrated previously and in this study, are of major importance. In view of the available literature demonstrating the effects of exogenously added CS on cell viability, we hypothesized that ECS and EO in particular may have an effect on cell viability. The experimental approach implemented in the present study to address this issue was to reduce serum EO and test for the biological outcome of this perturbation. This was achieved by treating bovine serum with anti-ouabain antibodies and testing the effect of media containing this serum on cell viability. This treatment caused a specific reduction in serum EO levels without affecting those of other tested steroids or hormones (Fig. 2) . Our results confirm that the effect of the anti-ouabain antibodies on cell viability is indeed due to the decrease in the EO in the medium, as the effect was not evident when the antibodies were added to serum-free medium (Fig. 4B ) and was partially reversed by the addition of exogenous ouabain (Fig.  4C) . It is noteworthy that the concentrations of exogenously added ouabain that elicit a stimulation in cell viability are in the same order of magnitude as the circulating EO levels (Ref. 6 and Fig. 1 ). This suggests that the effect of EO on cell viability is of physiological relevance. The effect of EO on cell viability Fig. 9 . Effect of anti-ouabain antibodies on serum-induced ERK activation. NT2 and PC12 cells were cultured for 24 h in complete medium. Following a 24-h incubation in serum-free medium, serum-free and complete medium previously preincubated with anti-ouabain antibodies or IgG (50 g/ml) were added for 20 min. ERK activation was determined as described in Fig. 7 . Values are expressed as the means Ϯ SE (error bars; n ϭ 5; *P Ͻ 0.05, **P Ͻ 0.01).
is cell specific. In our study, PC12 and OK cell viability was not affected by the reduction in EO in their growth medium (Fig. 2) . The mechanism underlying this cell specificity is not known and is currently under investigation in our laboratory. Interestingly, the reduction in serum EO decreased NT2 cell viability to the level observed in serum-free medium (Fig. 4) . This implies that EO not only has a stimulatory effect on cell viability but also may affect stimulation of growth caused by other growth factors. Indeed, numerous studies (12, 30) have shown a tight crosstalk between several growth factors, including insulin, insulin growth factor -1, and EGF with Na ϩ -K ϩ -ATPase and CS, although the mechanisms involved in these interactions are yet to be elucidated.
The effects of exogenous ouabain and the reduction in medium EO on PC12 cells differed from the effects on NT2 cells. Whereas the addition of ouabain increased the viability of both cell lines (Figs. 5 and 6 ), the reduction in serum EO lowered the viability of NT2 but not of PC12 cells (Fig. 4A) . EO was shown to be synthesized in and released from PC12 cells (29) . Hence, it is feasible that the released EO from PC12 cells compensates for the reduction in EO following the addition of the anti-ouabain antibodies and accounts for their lack of effect on viability in these cells. However, despite the presence of EO in PC12 cell medium, the addition of exogenous ouabain stimulated their viability (Fig. 6 ). This paradoxical lack of effect of the anti-ouabain antibodies on PC12 cell viability, in view of the increased viability by exogenously added ouabain, may result from different experimental conditions. Whereas the first was found in serum-supplemented medium, the second was in serum-free medium. Alternatively, the stimulatory effect of the exogenous ouabain may indicate that the mechanisms involved in the EO-induced increase in PC12 cell viability are not saturated at EO concentrations and can be further stimulated when ouabain concentrations are increased.
The activation of ERK1/2 plays an important role, largely through regulation of gene transcription, in a number of cellular processes including cell proliferation, DNA synthesis, differentiation, and survival (9, 15) . When the cells were incubated in the presence of ouabain, a significant increase in ERK1/2 phosphorylation was observed (Fig. 7) . The present study confirms the causal relation between the ouabain-induced increase in cell viability and its effect on ERK1/2 phosphorylation. This was previously demonstrated by other groups working on several cell types (see Introduction). We have shown here that the ouabain-induced increase in NT2 cell growth was preceded by an increase in ERK1/2 phosphorylation (Fig. 7) and the two effects were inhibited by the specific inhibitor of the ERK1/2 signaling pathway U0126 (Fig. 8) . However, ERK1/2 phosphorylation was also induced by bufalin (Fig. 7) , which did not stimulate NT2 or PC12 cell viability. Hence, it can be concluded that additional mechanisms to ERK1/2 activation are needed for the ouabain-induced increase in cell viability.
In view of the presence of EO as well as endogenous bufadienolides in mammalian tissues and circulation, the effect of ouabain on NT2 and PC12 cell viability and proliferation and ERK1/2 activation was compared with the effects of the bufadienolide bufalin (Figs. 5-7) . We observed marked differences between the effects of the two compounds. Whereas ouabain stimulated the viability of the two cell lines and activated ERK1/2 in NT2 cells, bufalin did not stimulate growth but did activate ERK1/2 in NT2 cells. This difference in activity serves as an additional example of the diversity in the actions of different CS. Previous reports demonstrated that despite the overall similarity in structure, the effects of different CS at the molecular, cellular and in vivo levels are extremely diverse (for review, see Ref. 6) . Furthermore, in a study of the activity of CS on heart muscle contractility and rhythm, it was shown that different CS are even antagonistic to the effects of others (47) . This diversity of action of the different CS may be of significance when considering the putative physiological roles of the different ECS.
As the two cell lines studied here, NT2 and PC12, are of neuronal and endocrine origin, respectively, the implication of our findings on neuronal cell death and viability deserves specific consideration. It is now well established that neurons and glial cells, in the central or peripheral nervous system, are capable of synthesizing neurosteroids that regulate several neurophysiological functions (for review, see Ref. 45 ). The functions attributed to specific neurosteroids include regulation of excitatory and inhibitory synaptic transmission, neurotransmitter release and remyelinization, neuroprotection, and growth of axons and dendrites (11) . The involvement of the Na ϩ -K ϩ -ATPase/CS system in brain function is well recognized: the interaction of CS with Na ϩ -K ϩ -ATPase has profound effects on the neuronal electrical resting potential, basal metabolic rate of neurons and glia, and the release and reuptake of several neurotransmitters (for review, see Ref. 36) . In view of the presence of EO and other ECS in the brain and CSF, it is tempting to suggest that these compounds are neurosteroids which, according to the present findings, affect neuronal cell viability and may be of relevance in the etiology of these maladies.
